Advertisement

Royalty Pharma plc RPRX

Set alert

Price alert · RPRX

All alert types
66.52 USD -0.66 -0.98%

At close · Nov 2

66.52 0.00 0.00%

After hours · Nov 2, 4:00 PM ET

Bid
66.52 × 2
Ask
66.53 × 2
66.43 Day range 67.10
36.03 52-week range 67.71
YTD
+72.15%
1 year
+77.20%
Open
66.97
Prev close
67.18
Mkt cap
38.44B
Vol
2.87M
Avg vol
3.08M
EPS
1.88
P/E
35.38
Div yield
1.40%
More statistics
Low
66.43
High
67.10
Forward P/E
11.45
Beta
0.36
Short ratio
4.30
Inst. own
90.20%
Dividend
0.94
Ex-div date
Nov 12, 2026
Earnings
Nov 4, 2026
50-d avg
60.28
200-d avg
53.22
1y target
65.38

1D chart

Chart tools
Interval

Signals (92)
NameTimeAgo
RSI: Oversold3:58 PM2 hours ago
SMA: Bearish3:43 PM2 hours ago
MACD: Sell Signal3:43 PM2 hours ago
SMA: Bullish3:41 PM2 hours ago
MACD: Buy Signal3:41 PM2 hours ago
SMA: Bullish3:36 PM2 hours ago
SMA: Bearish3:31 PM2 hours ago
SMA: Bearish3:24 PM2 hours ago
MACD: Sell Signal3:14 PM3 hours ago
MACD: Buy Signal3:01 PM3 hours ago
SMA: Bullish2:59 PM3 hours ago
SMA: Bullish2:59 PM3 hours ago
SMA: Bearish2:58 PM3 hours ago
SMA: Bearish2:57 PM3 hours ago
MACD: Sell Signal2:52 PM3 hours ago
RSI: Overbought2:46 PM3 hours ago
SMA: Bullish2:36 PM3 hours ago
SMA: Bearish2:35 PM3 hours ago
SMA: Bullish2:34 PM3 hours ago
SMA: Bearish2:32 PM3 hours ago
SMA: Bullish2:29 PM3 hours ago
SMA: Bearish2:28 PM3 hours ago
MACD: Buy Signal2:28 PM3 hours ago
SMA: Bullish2:27 PM3 hours ago
SMA: Bullish2:25 PM3 hours ago
SMA: Bearish2:17 PM3 hours ago
SMA: Bearish2:17 PM3 hours ago
MACD: Sell Signal2:13 PM4 hours ago
SMA: Bullish1:59 PM4 hours ago
SMA: Bullish1:55 PM4 hours ago
MACD: Buy Signal1:52 PM4 hours ago
MACD: Sell Signal1:50 PM4 hours ago
MACD: Buy Signal1:49 PM4 hours ago
RSI: Oversold1:41 PM4 hours ago
MACD: Sell Signal1:31 PM4 hours ago
SMA: Bearish1:30 PM4 hours ago
SMA: Bullish1:26 PM4 hours ago
MACD: Buy Signal1:26 PM4 hours ago
SMA: Bullish1:19 PM4 hours ago
SMA: Bullish1:19 PM4 hours ago
SMA: Bearish1:16 PM5 hours ago
MACD: Sell Signal1:15 PM5 hours ago
SMA: Bearish1:14 PM5 hours ago
SMA: Bullish1:06 PM5 hours ago
SMA: Bullish1:04 PM5 hours ago
SMA: Bearish1:03 PM5 hours ago
SMA: Bearish1:00 PM5 hours ago
SMA: Bullish12:59 PM5 hours ago
SMA: Bullish12:58 PM5 hours ago
MACD: Buy Signal12:53 PM5 hours ago
RSI: Oversold12:48 PM5 hours ago
RSI: Oversold12:43 PM5 hours ago
MACD: Sell Signal12:28 PM5 hours ago
SMA: Bearish12:25 PM5 hours ago
SMA: Bearish12:25 PM5 hours ago
SMA: Bullish12:23 PM5 hours ago
SMA: Bullish12:22 PM5 hours ago
MACD: Buy Signal12:16 PM6 hours ago
SMA: Bearish12:05 PM6 hours ago
SMA: Bullish12:02 PM6 hours ago
SMA: Bearish11:58 AM6 hours ago
SMA: Bearish11:58 AM6 hours ago
MACD: Sell Signal11:58 AM6 hours ago
RSI: Overbought11:57 AM6 hours ago
SMA: Bullish11:40 AM6 hours ago
SMA: Bullish11:35 AM6 hours ago
MACD: Buy Signal11:28 AM6 hours ago
SMA: Bearish11:11 AM7 hours ago
SMA: Bullish11:06 AM7 hours ago
SMA: Bearish11:05 AM7 hours ago
MACD: Sell Signal10:57 AM7 hours ago
SMA: Bullish10:45 AM7 hours ago
SMA: Bullish10:45 AM7 hours ago
SMA: Bearish10:43 AM7 hours ago
SMA: Bearish10:41 AM7 hours ago
MACD: Buy Signal10:39 AM7 hours ago
SMA: Bullish10:38 AM7 hours ago
SMA: Bullish10:38 AM7 hours ago
SMA: Bearish10:30 AM7 hours ago
SMA: Bearish10:30 AM7 hours ago
MACD: Sell Signal10:30 AM7 hours ago
SMA: Bullish10:23 AM7 hours ago
SMA: Bullish10:23 AM7 hours ago
MACD: Buy Signal10:23 AM7 hours ago
MACD: Sell Signal10:22 AM7 hours ago
SMA: Bearish10:21 AM7 hours ago
SMA: Bearish10:21 AM7 hours ago
SMA: Bullish10:19 AM7 hours ago
SMA: Bearish10:18 AM7 hours ago
MACD: Buy Signal10:17 AM7 hours ago
SMA: Bullish10:16 AM8 hours ago
SMA: Bearish10:04 AM8 hours ago

Key statistics

Market cap
38.44B
Enterprise value
40.99B
Trailing P/E
35.38
Forward P/E
11.45
PEG ratio
1.57
Price / sales
15.16
Price / book
4.34
EPS (TTM)
1.88
Beta
0.36
Dividend yield
1.40%
Payout ratio
48.40%
Profit margin
32.02%
Revenue (TTM)
2.54B
Revenue growth
16.50%
Free cash flow
-1.20B
Total cash
836.99M
Total debt
8.96B
Return on equity
13.96%
Shares outstanding
445.28M
Short % of float
2.92%
50-day average
60.28
200-day average
53.22

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 65.38 -1.7% downside
Target (low)
61.00
Target (mean)
65.38
Target (high)
70.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
  • Strong buy2
  • Buy5
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Nov 4, 2026

Expected Nov 4, 2026. Consensus EPS estimate 1.18.

Earnings history

Financials — quick view

All financials
RPRX Revenue — quarterly 674.14M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
RPRX Net income — quarterly 17.88M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
RPRX EPS — quarterly 0.04
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

RPRX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 30, 20261.18———
Aug 5, 2026Jun 30, 20261.271.32+0.05+3.94%
May 6, 2026Mar 31, 20261.211.30+0.09+7.44%
Feb 11, 2026Dec 31, 20251.291.46+0.17+13.18%
Nov 5, 2025Sep 30, 20250.9941.17+0.18+17.71%
Aug 6, 2025Jun 30, 20251.031.14+0.11+10.68%

Upgrades / downgrades

RPRX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 7, 2026Morgan StanleymainOverweightOverweight
Sep 8, 2026TD CowenmainBuyBuy
Aug 7, 2026JP MorganmainOverweightOverweight
Jul 13, 2026TD CowenmainBuyBuy
May 7, 2026CitigroupmainBuyBuy
May 7, 2026JP MorganmainOverweightOverweight

About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on RPRX — it syncs with the Stock Master app.

Insider holders

RPRX insider holders
InsiderRelationLatest transactionDateShares held
BASSLER BONNIE LDirectorStock Award(Grant)Sep 29, 202679,823
COYNE TERRANCE PChief Financial OfficerSaleAug 12, 20260
DESOUZA ERROL BDirectorStock Award(Grant)May 12, 202581,352
ENGELBERT CATHERINE M.DirectorStock Award(Grant)Jun 4, 202655,673
FERNANDEZ HENRY ADirectorStock Award(Grant)Jun 29, 2025123,524
HITE CHRISTOPHEROfficerSaleSep 21, 20260

Institution ownership

RPRX institution ownership
Holder% heldSharesValueReported
Morgan Stanley9.64%42,931,5972.86BJun 29, 2026
Capital International Investors7.92%35,273,7702.35BJun 29, 2026
Blackrock Inc.6.25%27,832,9771.85BJun 29, 2026
FMR, LLC5.51%24,513,8141.63BJun 29, 2026
State Street Corporation2.77%12,338,229820.74MJun 29, 2026
Price (T.Rowe) Associates Inc2.51%11,193,657744.60MJun 29, 2026

Fund ownership

RPRX fund ownership
Holder% heldSharesValueReported
NEW PERSPECTIVE FUND4.34%19,337,5351.29BSep 29, 2026
Capital Income Builder1.67%7,427,586494.08MSep 29, 2026
Growth Fund of America1.52%6,747,312448.83MSep 29, 2026
MORGAN STANLEY INSTITUTIONAL FUND INC-GROWTH PORTFOLIO1.10%4,910,932326.68MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.00%4,471,210297.42MJun 29, 2026
TR PRICE-Price (T.Rowe) U.S. Value Equity Trust0.95%4,232,023281.51MJun 29, 2026
Advertisement